פרדניזון 5 מג
rekah pharmaceutical industry ltd, israel - prednisone - טבליה - prednisone 5 mg - prednisone - prednisone - anti-inflammatory.
פרדניזון 20 מג
rekah pharmaceutical industry ltd, israel - prednisone - טבליה - prednisone 20 mg - prednisone - prednisone - anti-inflammatory for treatment of inflammation responsive to glucocorticosteroids such as: acute allergies, rheumataid arthritis.
פרדניזון 1 מג טבליות
rekah pharmaceutical industry ltd, israel - prednisone - טבליה - prednisone 1 mg - prednisone - prednisone - anti-inflammatory.
לודוטרה 1
rafa laboratories ltd - prednisone 1 mg - tablets modified release - prednisone - for the treatment of moderate to severe, active rheumatoid arthritis in adults particularly when accompanied by morning stiffness
לודוטרה 1
rafa laboratories ltd - prednisone 1 mg - tablets modified release - prednisone - for the treatment of moderate to severe, active rheumatoid arthritis in adults particularly when accompanied by morning stiffness
לודוטרה 2
rafa laboratories ltd - prednisone 2 mg - tablets modified release - prednisone - for the treatment of moderate to severe, active rheumatoid arthritis in adults particularly when accompanied by morning stiffness
לודוטרה 2
rafa laboratories ltd - prednisone 2 mg - tablets modified release - prednisone - for the treatment of moderate to severe, active rheumatoid arthritis in adults particularly when accompanied by morning stiffness
לודוטרה 5
rafa laboratories ltd - prednisone 5 mg - tablets modified release - prednisone - for the treatment of moderate to severe, active rheumatoid arthritis in adults particularly when accompanied by morning stiffness
לודוטרה 5
rafa laboratories ltd - prednisone 5 mg - tablets modified release - prednisone - for the treatment of moderate to severe, active rheumatoid arthritis in adults particularly when accompanied by morning stiffness
ג'בטאנה
sanofi israel ltd - cabazitaxel - תרכיז וממס להכנת תמיסה לאינפוזיה - cabazitaxel 60 mg / 1.5 ml - cabazitaxel - cabazitaxel - in combination with prednisone for the treatment of patients with metastatic hormone refractory prostate cancer (mhrpc) previously treated with a docetaxel-based treatment regimen